Supernus: Sales Stretching Higher, But Not Reflected In Economic Leverage (NASDAQ:SUPN)

ozgurdonmaz Investment Briefing Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) is a biopharmaceutical company that specializes in developing and commercializing treatments for central nervous system (“CNS”) disorders. The company’s neuroscience portfolio comprises a range of approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (“ADHD”), and hypomobility in Parkinson’s Disease (“PD”). It currently has 8 commercial products in the…

Read More